To observe of the efficacy and safety of early initiation of budesonide enteric coated capsules in the treatment of primary IgA nephropathy.
Target patients aged 18-75, including those aged 18 and 75
Primary IgA nephropathy diagnosed by renal biopsy within 3 months
eGFR≥30ml/min/1.73m2
24-hour urine protein ≥ 1.0g/d, or UPCR ≥ 0.8 g/g
Including but not limited to secondary IgAN caused by allergic purpura, systemic lupus erythematosus, cirrhosis, rheumatoid arthritis, and ankylosing spondylitis
Patients who have received kidney transplantation or dialysis
Patients with other glomerular diseases (such as C3 glomerular disease and/or diabetes nephropathy) and nephrotic syndrome (i.e. proteinuria>3.5 g/d, serum albumin<3.0 g/dl, with or without edema)
Patients with acute, chronic, or potential infectious diseases, including hepatitis, tuberculosis, human immunodeficiency virus, and chronic urinary tract infections